Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

For this latter group, the prognosis is very poor, according to AbbVie. Tepkinly (known as Epkinly in some markets) was approved for use in DLBCL on the back of the phase 1/2 EPCORE study ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

The U.S. Food and Drug Administration (FDA) has approved the fourth indication for AbbVie's (NYSE:ABBV) anti-wrinkle therapy Botox Cosmetic, expanding its use beyond the face for the first time ...

AbbVie presents a strong long-term investment opportunity, driven by its strategic focus on neuroscience and IBD treatments, despite challenges from Humira's decline. Tavapadon and other ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

The latest trading session saw AbbVie (ABBV) ending at $188.57, denoting a -0.99% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.02%.

On Thursday, the FDA approved AbbVie Inc’s ABBV Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor fluctuations in ...